<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:04:14 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>FDA Approval of NULIBRY™ | BridgeBio</title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="Clinical trials with NULIBRY or recombinant cPMP showed a meaningful increase in overall survival compared to a natural history study. Learn more today!"
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta property="og:title" content="FDA Approval of NULIBRY™ | BridgeBio" />
    <meta
      property="og:description"
      content="Clinical trials with NULIBRY or recombinant cPMP showed a meaningful increase in overall survival compared to a natural history study. Learn more today!"
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2021-02-28T13:00:00+00:00"
    />
    <meta
      property="article:modified_time"
      content="2022-06-22T19:17:28+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2019/02/BridgeBio_Share.png"
    />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="600" />
    <meta property="og:image:type" content="image/png" />
    <meta name="author" content="Cybele Gouverneur" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Cybele Gouverneur" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="14 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin/",
            "name": "FDA Approval of NULIBRY™ | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "datePublished": "2021-02-28T13:00:00+00:00",
            "dateModified": "2022-06-22T19:17:28+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/0ccd4f21aad52916b60d0206bb498df7"
            },
            "description": "Clinical trials with NULIBRY or recombinant cPMP showed a meaningful increase in overall survival compared to a natural history study. Learn more today!",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin/"
                ]
              }
            ]
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/0ccd4f21aad52916b60d0206bb498df7",
            "name": "Cybele Gouverneur",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g",
              "caption": "Cybele Gouverneur"
            },
            "url": "https://bridgebio.com/author/cybele-gouverneur/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/style66eb.css?ver=1734517260"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-css66eb.css?ver=1734517260"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrust66eb.css?ver=1734517260"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scripts66eb.js?ver=1734517260"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modal66eb.js?ver=1734517260"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/3364.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../index9e5d.html?p=3364" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed839a.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embed060f?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-3364 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA
              Approval of NULIBRY™ (fosdenopterin), the First and Only Approved
              Therapy to Reduce the Risk of Mortality in Patients with MoCD Type
              A
            </h1>
            <section>
              <p>
                <em
                  >Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,
                  life-threatening genetic disorder that progresses rapidly,
                  results in severe and largely irreversible neurological
                  injury, and has a high infant mortality rate; median overall
                  survival age is about four years</em
                >
              </p>

              <p>
                <em
                  >Clinical trials with NULIBRY or recombinant cPMP showed a
                  meaningful increase in overall survival compared to a natural
                  history study</em
                >
              </p>

              <p>
                <em>NULIBRY is BridgeBio’s first FDA-approved therapeutic</em>
              </p>

              <p>
                PALO ALTO, February 28, 2021 – BridgeBio Pharma, Inc. (Nasdaq:
                BBIO) (BridgeBio) and affiliate Origin Biosciences, Inc.
                (Origin) today announced the U.S. Food and Drug Administration
                (FDA) has approved NULIBRY™ (fosdenopterin) for Injection as the
                first therapy to reduce the risk of mortality in patients with
                molybdenum cofactor deficiency (MoCD) Type A. This is the first
                therapy of its kind. The novel therapy was developed based on
                BridgeBio’s commitment to developing a treatment for MoCD Type A
                in collaboration with the experts and families in the MoCD Type
                A community. The announcement was made on Rare Disease Day,
                which aims to raise awareness about the impact of rare diseases
                on patients.
              </p>

              <p>
                MoCD Type A is an ultra-rare and progressive condition, known to
                impact less than 150 patients globally with a median survival of
                four years. MoCD Type A presents shortly after birth, often with
                severe encephalopathy and intractable seizures. NULIBRY is a
                first-in-class approved cPMP substrate replacement therapy.
              </p>

              <p>
                “The FDA’s approval of NULIBRY means that patients with MoCD
                Type A and their families have an approved therapy for the first
                time. It also reflects our belief that every life matters and
                that no disease is too rare to address. As is often true in rare
                disease drug development, this was a community effort in which
                we were able to play a part – we’d like to thank the patients,
                caregivers, physicians, scientists, and advocates who played an
                essential role in achieving this important milestone,” said
                BridgeBio founder and CEO Neil Kumar, Ph.D.
              </p>

              <p>
                The efficacy of NULIBRY for the treatment of patients with MoCD
                Type A was established based on data from three clinical trials
                compared to data from a natural history study. In these studies,
                NULIBRY or recombinant cPMP (rcPMP; same active moiety and
                biologic activity as NULIBRY) reduced the risk of death by 82%
                compared to the untreated, genotype-matched, historical control
                group in the natural history study (HR=0.18, 95% CI 0.04, 0.72).
                At three years on study, the probability of survival in NULIBRY
                or rcPMP-treated patients (n=13) was 84% (95% CI 49%,96%)
                compared to 55% (95% CI 30%,74%) for untreated genotype-matched
                patients in the historical control group (n=18) at three years
                (Figure 1). In addition to the survival analysis, treatment with
                NULIBRY led to a reduction of urine concentrations of
                S-sulfocysteine (SSC), a toxic substance that leads to
                neurological damage, in patients with MoCD Type A, and the
                reduction was sustained with long-term treatment over 48 months.
                 
              </p>

              <p>
                Animal studies have identified that NULIBRY has phototoxic
                potential. In the clinical trials, the most common adverse
                reactions reported in two or more Nulibry-treated patients with
                MoCD Type A were catheter-related complications (89%), pyrexia
                (fever; 78%), viral infection (56%), pneumonia (44%), otitis
                media (ear infection; 44%), vomiting (44%) and cough/sneezing
                (44%).  Adverse reactions for the rcPMP-treated patients were
                similar to the NULIBRY-treated patients.
              </p>

              <p>
                “Today’s approval represents new hope for patients and families
                affected with MoCD Type A,” said Donald Basel, M.D., section
                chief and associate professor of pediatrics at Children’s
                Wisconsin. “I am encouraged by the clinical data showing that
                NULIBRY not only lowers the levels of toxic SSC, but importantly
                extends the lives of patients who previously had only a three-
                to four-year median survival.” 
              </p>

              <p>
                NULIBRY was reviewed under Priority Review and received Orphan
                Drug Designation, Breakthrough Therapy Designation and Rare
                Pediatric Disease Designation from the FDA. With this approval,
                the FDA also issued a Rare Pediatric Disease Priority Review
                Voucher (PRV) to Origin.
              </p>

              <p>
                BridgeBio and Origin are committed to patient access and have
                developed a comprehensive patient support program,
                ForgingBridges, to help patients access NULIBRY. ForgingBridges
                also provides tools and resources to help patients and
                caregivers throughout their treatment journey with NULIBRY.
              </p>

              <p>
                Visit NULIBRY.com for more information, including full
                Prescribing Information.
              </p>

              <p>
                <strong
                  >About Molybdenum Cofactor Deficiency (MoCD) Type A</strong
                ><br />MoCD Type A is an autosomal recessive, inborn error of
                metabolism caused by mutations in the molybdenum cofactor
                synthesis 1 gene (MOCS1) and characterized by a deficiency in
                molybdenum cofactor (MoCo) production, leading to a lack of
                molybdenum-dependent enzyme activity.<sup>1,2</sup>  The lack of
                activity leads to decreased sulfite oxidase activity with
                buildup of sulfite and secondary metabolites (such as
                S-sulfocysteine (SSC)) in the brain, which causes irreversible
                neurological damage.<sup>2</sup>
              </p>

              <p>
                MoCD Type A is an ultra-rare disease. The incidence and
                prevalence of MoCD Type A in the United States are not known,
                but the estimated incidence is 1 per 342,000 to 411,000 live
                births (0.24 and 0.29 per 100,000).<sup>3</sup> Based on these
                estimates, MoCD Type A is likely to be underdiagnosed, with an
                estimated 22 to 26 missed diagnoses per year in the United
                States and European Union.
              </p>

              <p>
                The most common presenting symptoms of MoCD Type A are seizures,
                feeding difficulties and encephalopathy. Patients with MoCD Type
                A who survive beyond infancy typically suffer from progressive
                brain damage, which presents in characteristic patterns on
                magnetic resonance imaging (MRI). This damage leads to severe
                psychomotor impairment and an inability to make coordinated
                movements or communicate with their environment.
              </p>

              <p>
                <strong>About NULIBRY (</strong
                ><strong>fosdenopterin) for Injection</strong>
              </p>

              <p>
                NULIBRY (fosdenopterin) for Injection is a substrate replacement
                therapy that provides an exogenous source of cPMP, which is
                converted to molybdopterin. Molybdopterin is then converted to
                molybdenum cofactor, which is needed for the activation of
                molybdenum-dependent enzymes, including sulfite oxidase, an
                enzyme that reduces levels of neurotoxic sulfites. It is the
                first and only FDA-approved therapy indicated to reduce the risk
                of mortality in patients with MoCD Type A, and clinical trials
                have demonstrated that patients treated with NULIBRY or rcPMP
                had an improvement in overall survival compared to the
                untreated, genotype-matched, historical control group.
              </p>

              <p><strong>IMPORTANT SAFETY INFORMATION</strong></p>

              <p><strong>WARNINGS AND PRECAUTIONS</strong></p>

              <p><strong>Potential for Photosensitivity</strong></p>

              <p>
                NULIBRY can make the patient oversensitive to sunlight.
                NULIBRY-treated patients or their caregivers are advised to
                avoid or minimize patient exposure to sunlight and artificial UV
                light and adopt precautionary measures when exposed to the sun,
                including wearing protective clothing and sunglasses, and use
                broad-spectrum sunscreen with high SPF in patients 6 months of
                age and older. If photosensitivity occurs, caregivers/patients
                are advised to seek medical attention immediately and consider a
                dermatological evaluation.
              </p>

              <p><strong>ADVERSE REACTIONS</strong></p>

              <p>
                The most common adverse reactions in NULIBRY-treated patients
                were infusion catheter–related complications (89%), pyrexia
                (fever) (78%), viral infection (56%), pneumonia (44%), otitis
                media (ear infection) (44%), vomiting (44%), and cough/sneezing
                (44%). Adverse reactions for rcPMP-treated patients were similar
                to the NULIBRY-treated patients.
              </p>

              <p><strong>PATIENT COUNSELING INFORMATION</strong></p>

              <p>
                Please read the FDA-approved NULIBRY Prescribing Information and
                Instructions for Use and follow the instructions on how to
                prepare and administer NULIBRY.
              </p>

              <p>
                NULIBRY has a potential for photosensitivity; see Warnings and
                Precautions. Seek medical attention immediately if the patient
                develops a rash or if they notice symptoms of photosensitivity
                reactions (redness, burning sensation of the skin, blisters).
              </p>

              <p>
                You are encouraged to report negative side effects of
                prescription drugs to the FDA. Visit
                <a
                  href="https://www.fda.gov/medwatch"
                  target="_blank"
                  rel="noreferrer noopener"
                  >www.fda.gov/medwatch</a
                >, or call 1-800-FDA-1088.
              </p>

              <p>
                <strong>Clinical Trials<sup>4 </sup> </strong>
              </p>

              <p>
                The efficacy of NULIBRY for the treatment of patients with MoCD
                Type A was established based on data from three clinical trials
                compared to data from a natural history study. 
              </p>

              <p>
                Study 1: Study 1 was a prospective, open-label, single-arm,
                dose-escalation study in patients with MoCD Type A who were
                receiving treatment with rcPMP prior to treatment with NULIBRY. 
                Study 1 included eight patients, six of whom previously
                participated in Study 3. The initial NULIBRY dosage was matched
                to the patient’s rcPMP dosage upon entering the study. The
                NULIBRY dosage was then titrated over a period of five months to
                a maximum dosage of 0.9 mg/kg administered once daily as an
                intravenous infusion. 
              </p>

              <p>
                Study 2: Study 2 was a prospective, open-label, single-arm,
                dose-escalation study in one patient with confirmed MoCD Type A
                who had not been previously treated with rcPMP. The initial
                dosage of NULIBRY in Study 2 was based on the gestational age of
                the patient (i.e., 36 weeks).  The initial dosage was then
                incrementally escalated up to a maximum dosage of 0.98 mg/kg
                administered once daily as an intravenous infusion (1.1 times
                the maximum approved recommended dosage).
              </p>

              <p>
                Study 3: Study 3 was a retrospective, observational study that
                included 10 patients with a confirmed diagnosis of MoCD Type A
                who received rcPMP. Six of these 10 patients were later enrolled
                in Study 1 to receive treatment with NULIBRY.
              </p>

              <figure class="wp-block-image size-large">
                <img
                  fetchpriority="high"
                  decoding="async"
                  width="1024"
                  height="576"
                  class="wp-image-3365"
                  src="../../wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--1024x576.png"
                  alt=""
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--1024x576.png  1024w,
                    https://bridgebio.com/wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--300x169.png    300w,
                    https://bridgebio.com/wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--768x432.png    768w,
                    https://bridgebio.com/wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--1536x864.png  1536w,
                    https://bridgebio.com/wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--2048x1152.png 2048w,
                    https://bridgebio.com/wp-content/uploads/2021/02/Nulibry-Chart_Rev022421--1568x882.png  1568w
                  "
                  sizes="(max-width: 1024px) 100vw, 1024px"
                />
              </figure>

              <p class="has-small-font-size">
                Figure 1: Kaplan Meier Curve for Overall Survival in Patients
                with MoCD Type A Treated with NULIBRY (or rcPMP) Versus
                Genotype-Matched Untreated Patients in Historical Control
              </p>

              <p>
                <strong>NULIBRY Efficacy and Safety Data<sup>4</sup> </strong>
              </p>

              <p>
                The efficacy of NULIBRY and rcPMP were assessed in a combined
                analysis of the 13 patients with genetically confirmed MoCD Type
                A from Study 1 (n=8), Study 2 (n=1), and Study 3 (n=4), who
                received substrate replacement therapy with NULIBRY or rcPMP.  
              </p>

              <p>
                Of the 13 treated patients included in the combined analysis,
                54% were male, 77% were White and 23% were Asian; the median
                gestational age was 39 weeks (range 35 to 41 weeks). Of these 13
                treated patients, the age at first dose was ≤ 14 days for 10
                patients (with five patients initiating treatment at one day of
                age) and ≥32 days and &lt;69 days for the remaining three
                patients. 
              </p>

              <p>
                Efficacy was assessed by comparing overall survival in pediatric
                patients treated with NULIBRY or rcPMP (n=13) with an untreated
                natural history cohort of pediatric patients with genetically
                confirmed MoCD Type A who were genotype-matched to the treated
                patients (n=18). Patients treated with NULIBRY or rcPMP had an
                improvement in overall survival compared to the untreated,
                genotype-matched, historical control group. Results were similar
                when comparing treated patients with all patients in the
                untreated natural history cohort with genetically confirmed MoCD
                Type A (n=37, including the 18 genotype-matched untreated
                patients as well as 19 additional untreated patients who were
                not genotype-matched).
              </p>

              <p>
                Treatment with NULIBRY resulted in a reduction of urine
                concentrations of SSC in patients with MoCD Type A, and the
                reduction was sustained with long-term treatment over 48 months.
                The baseline level of urinary SSC normalized to creatinine was
                characterized in one patient (Study 2) with a value of 89.8
                umol/mmol. Following treatment with NULIBRY in Studies 1 and 2
                (n=9), the mean±SD levels of urinary SSC normalized to
                creatinine ranged from 11 (±8.5) to 7 (±2.4) umol/mmol from
                month 3 to month 48. 
              </p>

              <p>
                The safety of NULIBRY was assessed in 37 pediatric patients and
                healthy adults who received at least one intravenous infusion of
                NULIBRY or rcPMP. Of these 37 patients/healthy adults, 13 were
                pediatric patients with MoCD Type A in Studies 1, 2 and 3; six
                were pediatric patients with presumptive MoCD Type A but who
                were later confirmed to not have MoCD type A; and 18 were
                healthy adults (without MoCD Type A) in a Phase 1 study. 
              </p>

              <p>
                The most common adverse reactions from NULIBRY-treated patients
                in Studies 1 and 2 were catheter-related complications, pyrexia
                (fever), viral infection, pneumonia, otitis media (ear
                infection), vomiting and cough/sneezing. Adverse reactions for
                the rcPMP-treated patients from Study 3 were similar to the
                NULIBRY-treated patients, with the exception of the following
                additional adverse reactions that were reported in more than one
                patient: sepsis, oral candidiasis, varicella, fungal skin
                infection and eczema.
              </p>

              <p>
                <strong>About Origin Biosciences, Inc.</strong><br />Origin
                Biosciences, Inc., an affiliate of BridgeBio Pharma, Inc., is a
                biotechnology company that developed and commercialized NULIBRY
                for the treatment of patients with a diagnosis or presumptive
                diagnosis of MoCD Type A. Origin Biosciences, Inc. is led by a
                team of veteran biotechnology executives. For more information
                on Origin Biosciences, Inc., please visit the company&#8217;s
                website at <strong
                  ><a
                    href="https://www.globenewswire.com/Tracker?data=2DEmasLkKXTr6KSLNWS_DK85lXMHl2afPNsLIBCVW7Gc7MWYRHdza-a8PetgrLEP1f3d-JtIgP3NAtI07U72kw=="
                    target="_blank"
                    rel="noreferrer noopener"
                    >www.origintx.com</a
                  ></strong
                >.
              </p>

              <p>
                <strong>About BridgeBio Pharma, Inc.<br /></strong
                ><a
                  href="../../index.html"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>BridgeBio</strong></a
                > is a team of experienced drug discoverers, developers and
                innovators working to create life-altering medicines that target
                well-characterized genetic diseases at their source. BridgeBio
                was founded in 2015 to identify and advance transformative
                medicines to treat patients who suffer from Mendelian diseases,
                which are diseases that arise from defects in a single gene, and
                cancers with clear genetic drivers. BridgeBio’s pipeline of over
                30 development programs includes product candidates ranging from
                early discovery to late-stage development. For more information
                visit <a
                  href="../../index.html"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                >.
              </p>

              <p>
                <strong
                  >BridgeBio Pharma Forward-Looking Statements<br /></strong
                >This press release contains forward-looking statements. 
                Statements we make in this press release may include statements
                that are not historical facts and are considered forward-looking
                within the meaning of Section 27A of the Securities Act of 1933,
                as amended (the Securities Act), and Section 21E of the
                Securities Exchange Act of 1934, as amended (the Exchange Act),
                which are usually identified by the use of words such as
                “anticipates,” “believes,” “estimates,” “expects,” “intends,”
                “may,” “plans,” “projects,” “seeks,” “should,” “will,” and
                variations of such words or similar expressions.  We intend
                these forward-looking statements to be covered by the safe
                harbor provisions for forward-looking statements contained in
                Section 27A of the Securities Act and Section 21E of the
                Exchange Act, and are making this statement for purposes of
                complying with those safe harbor provisions.  These
                forward-looking statements, including statements relating to:
                the development by Origin Biosciences, Inc. (Origin) of NULIBRY™
                (fosdenopterin) for Injection as the first therapy approved by
                the U.S. Food and Drug Administration (FDA) to reduce the risk
                of mortality in patients with molybdenum cofactor deficiency
                (MoCD) Type A; the potential for NULIBRY as the first and only
                FDA approved therapy for MoCD Type A; the efficacy of NULIBRY
                for the treatment of patients with MoCD Type A; the safety
                profile of NULIBRY for the treatment of patients with MoCD Type
                A, including the most common adverse reactions; BridgeBio’s
                belief that every life matters and that no disease is too rare
                to address; the potential for NULIBRY to lower the levels of
                toxic S-sulfocysteine (SSC) and extend the lives of treated
                patients; the ability of NULIBRY to retain Orphan Drug
                Designation, Breakthrough Therapy Designation and Rare Pediatric
                Disease Designation from the FDA; the ability of ForgingBridges
                to be a comprehensive patient support program and help patients
                access NULIBRY; plans for the supply, manufacturing and
                distribution of NULIBRY; the incidence and prevalence of MoCD
                Type A; the current FDA-approved NULIBRY Prescribing Information
                and Instructions for Use; the planned approval of NULIBRY by
                foreign regulatory authorities and the necessary clinical trial
                results, and timing and completion of regulatory submissions
                related thereto; and the competitive environment and clinical
                and therapeutic potential of NULIBRY, reflect our current views
                about our plans, intentions, expectations, strategies and
                prospects, which are based on the information currently
                available to us and on assumptions we have made.  Although we
                believe that our plans, intentions, expectations, strategies and
                prospects as reflected in or suggested by those forward-looking
                statements are reasonable, we can give no assurance that the
                plans, intentions, expectations or strategies will be attained
                or achieved.  Furthermore, actual results may differ materially
                from those described in the forward-looking statements and will
                be affected by a variety of risks and factors that are beyond
                our control including, without limitation: the fact that there
                has never been an approved therapy for MoCD Type A; the safety,
                tolerability and efficacy profile of NULIBRY observed to date
                may change adversely in ongoing analyses of trial data or
                subsequent to commercialization; despite having ongoing
                interactions with the FDA or other regulatory agencies, the FDA
                or such other regulatory agencies may not agree with Origin’s
                regulatory approval strategies, components of our filings, such
                as clinical trial designs, conduct and methodologies, or the
                sufficiency of data submitted; Origin may encounter delays in
                meeting manufacturing or supply timelines or disruptions in its
                distribution plans for NULIBRY; whether and when any regulatory
                submissions may be filed in various foreign jurisdictions and
                ultimately approved by foreign regulatory authorities; and
                potential adverse impacts due to the global COVID-19 pandemic
                such as delays in regulatory review, manufacturing and clinical
                trials, supply chain interruptions, adverse effects on
                healthcare systems and disruption of the global economy;  as
                well as those set forth in the Risk Factors section of BridgeBio
                Pharma, Inc.’s most recent Annual Report on Form 10-K filed with
                the U.S. Securities and Exchange Commission (SEC) and in
                subsequent SEC filings, which are available on the SEC’s website
                at <a
                  href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52351619&amp;newsitemid=20201218005748&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=17&amp;md5=0af1f9fdc90bcab8124c083ab773d1cb"
                  target="_blank"
                  rel="noreferrer noopener"
                  >www.sec.gov</a
                >.  Except as required by law, each of BridgeBio and Origin
                disclaims any intention or responsibility for updating or
                revising any forward-looking statements contained in this press
                release in the event of new information, future developments or
                otherwise. Moreover, BridgeBio and Origin operate in a very
                competitive environment in which new risks emerge from time to
                time. These forward-looking statements are based on each of
                BridgeBio’s and Origin’s current expectations, and speak only as
                of the date hereof.
              </p>

              <p>
                <strong>References </strong><br /><sup>1</sup>Mechler K et al.
                Genet Med. 2015;17(12):965-970.<br /><sup>2</sup>Schwarz G. Cur
                Op in Che Bio. 2016;31:179-187.<br /><sup>3</sup>Mayr SJ, et al.
                Forecasting the incidence of rare diseases: an iterative
                computational and biochemical approach in molybdenum cofactor
                deficiency type A. Presented at the 2019 SSIEM meeting;
                September 3-6, 2019; Rotterdam, The Netherlands.<br /><sup
                  >4</sup
                >NULIBRY (fosdenopterin) Origin Biosciences, Palo Alto, CA, USA;
                February 2021.
              </p>

              <p>
                NOTE: NULIBRY is a trademark of Origin Biosciences, Inc. Origin
                Biosciences, Inc. is a member of the BridgeBio family.
                ForgingBridges is a trademark of BridgeBio.
              </p>

              <p>
                Contact:<br />Grace Rauh<br /><a
                  href="../../cdn-cgi/l/email-protection.html#9cfbeefdfff9b2eefde9f4dcfeeef5f8fbf9fef5f3f8f9eab2ebecf9f2fbf5f2f9b2fff3f1"
                  ><span
                    class="__cf_email__"
                    data-cfemail="086f7a696b6d267a697d60486a7a616c6f6d6a61676c6d7e267f786d666f61666d266b6765"
                    >[email&#160;protected]</span
                  ></a
                ><br />(917) 232-5478
              </p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4>
              <a href="../archive/index.html" class="red uppercase"
                >News Archive</a
              >
            </h4>
            <small class="date">02.28.2021</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#20494e464f6042524944474542494f0e434f4d"
              ><span
                class="__cf_email__"
                data-cfemail="472e2921280725352e232022252e286924282a"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
